Liraglutide improves adipose tissue remodeling and mitochondrial dynamics in a visceral obesity model induced by a high-fat diet

Central obesity is characterized by visceral adipose tissue (VAT) expansion, considered one of the main risk factors for metabolic complications. In recent years, new drugs have been studied for obesity treatment. Liraglutide (LGT), a GLP-1 agonist, decreases body weight, however, several mechanisms...

Full description

Saved in:
Bibliographic Details
Published in:Current research in pharmacology and drug discovery 2024-01, Vol.6, p.100185, Article 100185
Main Authors: Touceda, Vanessa, Fontana Estevez, Florencia, Cacciagiú, Leonardo, Finocchietto, Paola, Bustos, Romina, Vidal, Agustina, Berg, Gabriela, Morales, Celina, González, Germán E., Miksztowicz, Veronica
Format: Article
Language:English
Subjects:
Liraglutide
Metalloproteinase
Vascular density
Visceral adipose tissue
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Central obesity is characterized by visceral adipose tissue (VAT) expansion, considered one of the main risk factors for metabolic complications. In recent years, new drugs have been studied for obesity treatment. Liraglutide (LGT), a GLP-1 agonist, decreases body weight, however, several mechanisms of action on VAT are still unknown. to study the effect of LGT on factors associated with VAT remodeling and mitochondrial dynamics in mice fed a high-fat diet (HFD). C57BL/6 mice were divided into Control (C) and HFD. After 15 weeks of feeding, each group was subdivided according to LGT administration for 5 weeks: C, C + LGT, HFD, and HFD + LGT. In epididymal AT (EAT) we evaluated histological and mitochondrial characteristics, vascularity, gelatinase activity (MMPs), and galectin-3 expression. HFD presented larger adipocytes (p 
ISSN:2590-2571
2590-2571
DOI:10.1016/j.crphar.2024.100185